Protective effect of resveratrol against pembrolizumab-induced hepatotoxicity and neurotoxicity in male rats

dc.contributor.authorTurkmen, Nese B.
dc.contributor.authorYuce, Hande
dc.contributor.authorSahin, Yasemin
dc.contributor.authorTaslidere, Asli C.
dc.contributor.authorOzek, Dilan A.
dc.contributor.authorUnuvar, Songul
dc.contributor.authorCiftci, Osman
dc.date.accessioned2026-08-12T17:37:07Z
dc.date.issued2023
dc.departmentFırat Üniversitesi
dc.description.abstractThe present study investigates the effects of resveratrol (RSV) on brain and liver tissues in rats with pembrolizumab (PEMB)-induced toxicity. Obtained for the study were 28 male Sprague-Dawley rats (3-4 months old) which were divided into four groups: Group 1: Control. Group 2: Administered PEMB at 5 mg/kg/day i.p. for a week. Group 3: Administered RSV orally at the dose of 20 mg/kg/day for 30 days by gavage. Group 4: Administered PEMB and RSV at 20 and 5 mg/kg/day RSV, respectively, for 30 days. The results of this study revealed that PEMB leads to a significant increase in thiobarbituric acid reactive substance (TBARS) levels and a significant decrease in glutathione peroxidase (GPx), catalase (CAT), superoxide dismutase (SOD) activities, and glutathione (GSH) levels in the liver and brain tissues. The decreased SOD, CAT, GPx activities, and GSH levels increased significantly following RSV treatment in Group 4. The PEMB treatment showed histopathological alterations associated with strong positive cysteinyl aspartic acid-protease-3 (caspase-3) immunoreactivity, while RSV treatment reduced both the expression of caspase-3 protein and the histopathological changes. RSV administration prevents the biochemical, immunological, and histological alterations induced by PEMB. It can be suggested that the lower caspase-3 immunoreactivity in the PEMB + RSV group than in the PEMB group led to an inhibition of RSV on apoptosis.
dc.identifier.doi10.1002/jbt.23263
dc.identifier.issn1095-6670
dc.identifier.issn1099-0461
dc.identifier.issue3
dc.identifier.orcid0000-0003-2907-2019
dc.identifier.orcid0000-0001-9075-4807
dc.identifier.orcid0000-0001-5755-3560
dc.identifier.orcid0000-0001-8454-490X
dc.identifier.orcid0000-0003-3902-3210
dc.identifier.pmid36419233
dc.identifier.scopus2-s2.0-85142631308
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1002/jbt.23263
dc.identifier.urihttps://hdl.handle.net/11508/58194
dc.identifier.volume37
dc.identifier.wosWOS:000889868200001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofJournal of Biochemical and Molecular Toxicology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjecthepatotoxicity
dc.subjectneurotoxicity
dc.subjectoxidative stress
dc.subjectpembrolizumab
dc.subjectresveratrol
dc.titleProtective effect of resveratrol against pembrolizumab-induced hepatotoxicity and neurotoxicity in male rats
dc.typeArticle

Dosyalar